What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Portfolio Pulse from Benzinga Insights
Regeneron Pharmaceuticals (NASDAQ:REGN) has been analyzed by 19 analysts, showing a range of sentiments from bullish to bearish. Recent analyst actions have mostly been positive, with several raising their price targets. The average 12-month price target has increased by 6.42% to $1192.63. Regeneron shows strong financial performance with impressive net margins and low debt-to-equity ratio.
August 23, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Regeneron Pharmaceuticals has received mostly positive analyst ratings, with several analysts raising their price targets. The average 12-month price target has increased by 6.42% to $1192.63, indicating a positive outlook. The company's strong financial performance, including high net margins and low debt, supports this sentiment.
The majority of analysts have raised their price targets for Regeneron, reflecting a positive sentiment. The increase in the average price target by 6.42% suggests confidence in the company's future performance. Additionally, Regeneron's strong financial metrics, such as high net margins and low debt, further bolster the positive outlook.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100